Epilepsy – Current Treatment – Current Treatment: Physician Insights – Epilepsy (US)
For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving the dynamics of this stable market and offering safe and efficacious choices, especially for orphan subpopulations of the disease like LGS and DS. This report will explore neurologists’ perceptions of established and newly launched AEDs, their prescribing habits in today’s market, and anticipated changes in brand usage as more AEDs expand—and further complicate—prescriber choice.
Questions answered
- How are different epilepsy subpopulations (i.e., POS, GOS, LGS, and DS) treated today?
- How do product shares differ across lines of therapy? Are high-efficacy therapies factoring more into early-line treatment decisions?
- How has neurologists’ prescribing changed in the past year, and why? What further changes do they expect within the next year?
- What are neurologists’ opinions of the newest entrants in the epilepsy market, and how are they incorporating these AEDs in the treatment paradigm?
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: US
Primary research: Survey of 102 neurologists in the United States
Key drugs covered: Keppra, Lamictal, Depakene, Vimpat, Fycompa, Briviact, Xcopri, Epidiolex, Fintepla
Key companies: UCB, Sunovion, Biocodex, SK Biopharmaceuticals, GW Pharmaceuticals, Zogenix, Eisai
Key insights provided:
- Factors influencing disease management and treatment decisions.
- Drivers and constraints of treatment selection.
- Physician-reported treatment practices and brand-level patient shares.
- Rationale for changes in treatment approach.
- Physician insight on persistency and compliance.
- Physician-reported recent / anticipated changes in brand usage or treatment approach.
